伊匹木单抗/纳武利尤单抗对比标准治疗在非透明细胞肾细胞癌中的前瞻性随机II期试验——SUNNIFORECAST试验结果
SUNNIFORECAST试验将157例初治晚期或转移性非透明细胞肾细胞癌患者随机分配至伊匹木单抗/纳武利尤单抗组、152例至标准治疗组。12个月总生存率分别为78%与68%(P=0.026),中位总生存期分别为33.2个月与25.2个月(P=0.163,HR 0.81)。结论认为伊匹木单抗/纳武利尤单抗在12个月里程碑显示显著更长的总生存期且毒性可接受。
要点
- 12个月生存率伊匹木单抗/纳武利尤单抗组78% vs 标准治疗组68%,P=0.026。
- 中位总生存期33.2个月 vs 25.2个月,P=0.163,HR 0.81(0.61-1.099)。
- 因毒性停药分别为27例(17%)与13例(9%)。
核心结论
- 伊匹木单抗/纳武利尤单抗在12个月里程碑显示显著更长的总生存期且毒性谱可接受,作者认为其相较当前标准治疗在初治非透明细胞肾细胞癌中具有临床获益。
研究设计与样本
- 前瞻性随机II期试验,将初治晚期或转移性非透明细胞肾细胞癌成人患者按1:1随机分配至伊匹木单抗/纳武利尤单抗组或标准治疗组。
- 伊匹木单抗/纳武利尤单抗方案为纳武利尤单抗3 mg/kg联合伊匹木单抗1 mg/kg每3周共4剂,随后固定剂量纳武利尤单抗240 mg每2周或480 mg每4周。
- 按组织学和IMDC风险评分分层,中心病理复核为强制要求。
- 共157例分配至伊匹木单抗/纳武利尤单抗组,152例至标准治疗组。
- 主要终点为12个月总生存率,次要终点包括中位总生存期、缓解率、无进展生存期、安全性和生活质量。
主要发现
- 12个月生存率伊匹木单抗/纳武利尤单抗组78%(95%CI 71-84%)vs 标准治疗组68%(95%CI 60-75%),P=0.026。
- 中位总生存期伊匹木单抗/纳武利尤单抗组33.2个月 vs 标准治疗组25.2个月,P=0.163,HR 0.81(0.61-1.099)。
- 无进展生存期两组相似,HR 0.99(0.77-1.28)。
- 客观缓解率伊匹木单抗/纳武利尤单抗组32.8% vs 标准治疗组19.3%。
- 探索性分析显示PD-L1 CPS评分≥1与总生存期获益相关,HR 0.56(95%CI 0.37-0.86)。
关键数值与推荐
- 乳头状与非乳头状肾细胞癌亚型之间任何终点均未观察到主要差异。
- 因毒性治疗终止在伊匹木单抗/纳武利尤单抗组为27例(17%),标准治疗组为13例(9%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Non-clear cell renal cell cancers (nccRCCs) are a heterogeneous group of more than 20 different entities, but are rarely included in large, randomized trials. Tyrosine kinase inhibitors with or without immune checkpoint inhibition are considered as a standard of care (SOC), but optimal treatment is not yet defined. We designed the first prospective randomized trial comparing ipilimumab/nivolumab to SOC. PATIENTS AND METHODS: We randomized adult patients with previously untreated advanced or metastatic nccRCC 1:1 to nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for 4 doses followed by fixed dose nivolumab of 240 mg every 2 weeks or 480 mg every 4 weeks or to SOC. Patients were stratified by histology and by IMDC risk score. Central pathology review was mandatory. The primary endpoint was the overall survival (OS) rate at 12 months, secondary endpoints included median OS, response rate, progression-free survival (PFS), safety and quality of life. RESULTS: In total, 157 patients were assigned to receive ipilimumab/nivolumab, and 152 to SOC. The 12-month survival rate was 78% with ipilimumab/nivolumab [95% confidence interval (CI) 71-84%] compared to 68% with SOC (95% CI 60-75%, P = 0.026). Median OS was 33.2 months versus 25.2 months, P = 0.163 [HR 0.81 (0.61-1.099)]. PFS was similar in both arms [HR 0.99 (0.77-1.28)]. The ORR was 32.8% versus 19.3%. No major differences between papillary and non-papillary RCC subtypes were observed for any endpoint. Exploratory analysis showed a significant OS advantage [HR 0.56 (95% CI 0.37-0.86)] associated with a PD-L1 CPS score ≥1. Treatment discontinuation due to toxicity occurred in 27 patients (17%) with ipilimumab/nivolumab and 13 patients (9%) with SOC. CONCLUSIONS: Ipilimumab/nivolumab demonstrated a significantly longer OS at the 12-month milestone and an acceptable toxicity profile. Our results therefore underline a relevant clinical benefit of ipilimumab/nivolumab in previously untreated nccRCC entities compared to current SOC.
引用
- Bergmann L, Albiges L, Ahrens M, et al. Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial. Ann Oncol. 2025. PMID: 40180121. doi:10.1016/j.annonc.2025.03.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。